Shi‐Yong Sun

Also affiliated with Henan University, Winship Cancer Institute, Zhejiang University of Technology

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 25 papers. Top paper: “Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis”.

Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis

Cell Reports Methods(2021)10.1016/j.crmeth.2021.100050

N/A

0.510DataRank · unranked

29 citations

Qi Yu, Ronglai Shen, Shi‐Yong Sun, Carlos S. Moreno, Xiaoxian Li +2 more

Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer

Cancer Letters(2025)10.1016/j.canlet.2025.218010

N/A

0.208DataRank · unranked

3 citations

Karin A. Vallega, Dongsheng Wang, Elsa Bildtsen, Haian Fu, Suresh S. Ramalingam +3 more

Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung Cancer

Cancers(2025)10.3390/cancers17030446

N/A

0.189DataRank · unranked

2 citations

Abbe Pannucci, Andrei A. Ivanov, Jeffrey M. Switchenko, Shi‐Yong Sun, Gabriel Sica +5 more

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Cancer Research(2021)10.1158/0008-5472.can-21-0556

N/A

0DataRank · unranked

67 citations

Zhen Chen, Hongjing Zang, Songqing Fan, Jiajia Gu, Guojing Zhang +7 more

Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer

Acta Biomaterialia(2021)10.1016/j.actbio.2021.05.018

N/A

0DataRank · unranked

51 citations

Danlei Yu, Shi‐Yong Sun, Feng Li, Chen Wu

Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors

Molecular Cancer Research(2021)10.1158/1541-7786.mcr-21-0147

N/A

0DataRank · unranked

43 citations

Jianping Guo, Karin A. Vallega, C. Hu, Zhen Chen, Yunfu Deng +7 more

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling

Lung Cancer Targets and Therapy(2021)10.2147/lctt.s293902

N/A

0DataRank · unranked

23 citations

Wen Zhao, Karin A. Vallega, Shi‐Yong Sun, Danlei Yu

MET inhibition downregulates DR4 expression in MET-amplified lung cancer cells with acquired resistance to EGFR inhibitors through suppressing AP-1-mediated transcription

Neoplasia(2021)10.1016/j.neo.2021.06.006

N/A

0DataRank · unranked

12 citations

Karin A. Vallega, Shuo Zhang, Puyu Shi, Shi‐Yong Sun, Liang Deng

Multiplexed protein profiling reveals spatial subcellular signaling networks

iScience(2022)10.1016/j.isci.2022.104980

N/A

0DataRank · unranked

2 citations

Thomas Hu, Mythreye Venkatesan, Mayar Allam, Frank Schneider, Suresh S. Ramalingam +3 more

Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors

Chinese Medical Journal - Pulmonary and Critical Care Medicine(2023)10.1016/j.pccm.2022.10.001

N/A

0DataRank · unranked

15 citations

Shi‐Yong Sun

Data from The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis

(2023)10.1158/1535-7163.c.6531011

N/A

0DataRank · unranked

0 citations

Shuzhen Chen, Ping Yue, Timothy M. Acker, Benjamin Lefkove, Jack L. Arbiser +3 more

YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.11.006

N/A

0DataRank · unranked

165 citations

Bhakti Dwivedi, Zhengjia Chen, Chao Zhang, Benjamin G. Barwick, Vinicius Ernani +13 more

Data from Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

(2023)10.1158/0008-5472.c.6513256.v1

N/A

0DataRank · unranked

0 citations

Zhen Chen, Hongjing Zang, Songqing Fan, Jiajia Gu, Guojing Zhang +7 more

Data from Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response

(2023)10.1158/1078-0432.c.6518703.v1

N/A

0DataRank · unranked

0 citations

Junjie Chen, Yunkai Yu, Bo Li, Shi‐Yong Sun, Baolin Zhang +2 more

DNA topoisomerase II inhibition potentiates osimertinib’s therapeutic efficacy in EGFR-mutant non–small cell lung cancer models

Journal of Clinical Investigation(2024)10.1172/jci172716

N/A

0DataRank · unranked

30 citations

Karin A. Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang +4 more

Spatially resolved subcellular protein–protein interactomics in drug-perturbed lung-cancer cultures and tissues

Nature Biomedical Engineering(2024)10.1038/s41551-024-01271-x

N/A

0DataRank · unranked

15 citations

Thomas Hu, Abhijeet Venkataraman, Felix G. Rivera Moctezuma, Efe Ozturk, Nicholas Zhang +10 more

Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer

The Journal of Experimental Medicine(2024)10.1084/jem.20240435

N/A

0DataRank · unranked

15 citations

Karin A. Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang +4 more

Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer

Advanced Science(2024)10.1002/advs.202310126

N/A

0DataRank · unranked

10 citations

Karin A. Vallega, Vijay K. Boda, Zihan Quan, Dongsheng Wang, Songqing Fan +5 more

Intra-tumoral YAP and TAZ heterogeneity drives collective NSCLC invasion that is targeted by SUMOylation inhibitor TAK-981

iScience(2024)10.1016/j.isci.2024.111133

N/A

0DataRank · unranked

8 citations

Shagun Sharma, Pratik Shriwas, Labdhi Mehta, An H Vu, Janna K. Mouw +13 more

SHP2 ablation mitigates osteoarthritic cartilage degeneration by promoting chondrocyte anabolism through SOX9

The FASEB Journal(2024)10.1096/fj.202400642r

N/A

0DataRank · unranked

6 citations

Huiliang Yang, Changwei Wang, Mingliang Wang, Jiahui Huang, Thedoe Nyunt +8 more

Is tumor microenvironment important for targeted therapy in lung cancer?

Cancer Letters(2024)10.1016/j.canlet.2024.217203

N/A

0DataRank · unranked

3 citations

Shi‐Yong Sun

The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via MET inhibition

(2024)10.22541/au.170668621.16410191/v1

N/A

0DataRank · unranked

1 citations

Karin A. Vallega, Haiying Chen, Jia Zhou, Shi‐Yong Sun, Zhen Chen

Data from The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis

(2023)10.1158/1535-7163.c.6531011.v1

N/A

0DataRank · unranked

0 citations

Shuzhen Chen, Ping Yue, Timothy M. Acker, Benjamin Lefkove, Jack L. Arbiser +3 more

Overcoming acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)

Cancer(2020)10.1002/cncr.32744

N/A

0DataRank · unranked

48 citations

Guoqing Qian, Dan Zong, Songqing Fan, Taofeek K. Owonikoko, Suresh S. Ramalingam +2 more

The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of osimertinib, against NSCLC cells with acquired resistance to osimertinib due to MET amplification

Research Square (Research Square)(2020)10.21203/rs.3.rs-25317/v1

N/A

0DataRank · unranked

1 citations

Yiting Li, Kevin D.-Y. Sun, Jiajia Gu, Zhen Chen, Taofeek K Omonikoko +3 more